Key facts
- Proniras’s last known valuation is $17.5M (Jan 2025).
- It has raised $11.2M across 2 recorded rounds; the latest was Early Stage VC ($6.9M) in Dec 2023.
- Notable investors include Alexandria Venture Investments, ARCH Venture Partners, Johnson & Johnson JJDC, WRF Capital, Eli Lilly and Company Foundation — 9 tracked in total.
- Proniras has filed 4 Form Ds with the SEC since 2017, most recently Jan 2025 ($6.9M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Proniras
Funding rounds
2 roundsAbout Proniras
Operator of a clinical-stage biotechnology company intended for the development of novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system (CNS) disorders. The company offers parenteral medical countermeasure (MCM) therapies aimed at the development of drugs for the treatment of neurological conditions with high unmet medical needs, enabling medical researchers to antagonize glutamate signaling in the central nervous system.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2017
- Employees
- 4
- Website
- proniras.com/
- Ownership
- Privately Held (backing)
Proniras doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Proniras shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Proniras in its N-PORT filings yet. We sweep new filings monthly.